The neuroprotection market in North America is experiencing significant growth due to several key drivers such as the increasing prevalence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis in the region. As the aging population continues to rise, the demand for effective neuroprotective therapies and interventions is escalating. Additionally, advancements in medical technology and neuroscience research have led to the discovery of novel neuroprotective agents and treatment modalities, further propelling the market forward. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) has approved BOTOX for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Access sample report (including graphs, charts, and figures): https://univdatos.com/report/neuroprotection-market/get-a-free-sample-form.php?product_id=40570
Furthermore, North America boasts a robust healthcare infrastructure and a high level of connectivity among various stakeholders in the neuroprotection sector. The region has leading pharmaceutical companies, research institutions, and healthcare providers who collaborate closely to advance neuroprotective therapies. These factors will drive the growth of the market in the region in coming years.
Further, the North America neuroprotection market is expected to grow at a strong CAGR of 8% during the forecast period (2022-2030). The incidence of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis is increasing due to factors such as an aging population, genetic predisposition, and lifestyle factors. For instance, as per WHO, more than 55 million people were diagnosed with dementia in 2021, and there are nearly 10 million new cases every year. Also, in 2019, globally, 50 million people were diagnosed with epilepsy.
FIG. 1 North America Neuroprotection Market Revenue (2020-2030) – USD Mn
For a detailed analysis of the Global Neuroprotection Market browse through :- https://univdatos.com/report/neuroprotection-market/
Based on product type, the market is segmented into free radical trapping agents (antioxidants); apoptosis inhibitors; anti-inflammatory agents; glutamate antagonists (anti-excitotoxic agents); and others. The free radical trapping agents (antioxidants) category to witness higher CAGR during the forecast period owing to the aging population and the rising incidence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s are driving the demand for neuroprotection treatments which will further boost the growth of this segment.
On the basis of application, the market is categorized into neurodegenerative disorders, alzheimer’s disease, parkinson’s disease, multiple sclerosis, and other. Among these, the neurodegenerative disorders held a significant share in the market in 2021. This is mainly due to the increasing prevalence of neurodegenerative disorders, the growing awareness of the importance of maintaining brain health, and the need for effective treatments are driving the growth of the neuroprotection market. For instance, as per the International Agency for Research on Cancer, annual incidence rates of 10–15 per 100 000 have been noted in most surveys worldwide. Prevalence may reach 2% in persons aged 65 years and older.
Global Neuroprotection Market Segmentation
Market Insight, by Product Type
Market Insights, by Application
Market Insights, by End-Users
Market Insight, by Region
- North America U.S.
- Canada
- Rest of North America
- EuropeGermany
- UK
- France
- Italy
- Spain
- Rest of Europe
- APACChina
- India
- Japan
- Rest of APAC
- Rest of the World
Top Company Profiles
- AbbVie Inc.
- DAIICHI SANKYO COMPANY
- Astrocyte Pharmaceuticals
- AstraZeneca
- Biogen
- Novartis AG
- Lilly
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
- Merck KGaA